Long Non-coding RNA PVT1 as a Prognostic and Therapeutic Target in Pediatric Cancer
Boloix, Ariadna (Hospital Universitari Vall d'Hebron)
Masanas, Marc (Vall d'Hebron Institut de Recerca (VHIR))
Jiménez Jiménez, Carlos (Vall d'Hebron Institut de Recerca (VHIR))
Antonelli, Roberta (Vall d'Hebron Institut de Recerca (VHIR))
Soriano, Aroa (Vall d'Hebron Institut de Recerca (VHIR))
Roma, Josep (Vall d'Hebron Institut de Recerca (VHIR))
Sánchez de Toledo Codin, Josep (Vall d'Hebron Institut de Recerca (VHIR))
Gallego, Soledad (Vall d'Hebron Institut de Recerca (VHIR))
Segura, Miguel F. (Vall d'Hebron Institut de Recerca (VHIR))
Universitat Autònoma de Barcelona

Date:	2019
Abstract:	In recent decades, biomedical research has focused on understanding the functionality of the human translated genome, which represents a minor part of all genetic information transcribed from the human genome. However, researchers have become aware of the importance of non-coding RNA species that constitute the vast majority of the transcriptome. In addition to their crucial role in tissue development and homeostasis, mounting evidence shows non-coding RNA to be deregulated and functionally contributing to the development and progression of different types of human disease including cancer both in adults and children. Small non-coding RNAs (i. e. , microRNA) are in the vanguard of clinical research which revealed that RNA could be used as disease biomarkers or new therapeutic targets. Furthermore, many more expectations have been raised for long non-coding RNAs, by far the largest fraction of non-coding transcripts, and still fewer findings have been translated into clinical applications. In this review, we center on PVT1, a large and complex long non-coding RNA that usually confers oncogenic properties on different tumor types. We focus on the compilation of early advances in the field of pediatric tumors which often lags behind clinical improvements in adult tumors, and provide a rationale to continue studying PVT1 as a possible functional contributor to pediatric malignancies and as a potential prognostic marker or therapeutic target.
Grants:	Instituto de Salud Carlos III CP16/00006 Instituto de Salud Carlos III PI17/00564 Ministerio de Educación, Cultura y Deporte FPU16/01099
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	PVT1 ; Lncrna ; Epigenetic ; 8q32 ; Pediatric cancer
Published in:	Frontiers in Oncology, Vol. 9 (november 2019) , ISSN 2234-943X

DOI: 10.3389/fonc.2019.01173
PMID: 31781490

10 p, 1.1 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles